Results for:(20 found)
Jul 10, 2014 11:40AM on Top StocksBy Jim Cramer

Cheap money and greed from the Allergan bidder's side are strong incentives.

Jun 3, 2014 4:38PM on Top StocksBy Motley Fool

The company continues to woo Allergan, but the deal is anything but secure.

Tags: AGNVRX
May 12, 2014 2:30PM on Top StocksBy MSN Money Partner

American executives are scouring the world for tickets out of our tax system, bankers say.

Apr 22, 2014 11:04AM on Top StocksBy TheStreet.com Staff

Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman and Pershing Square Capital Management for a $47 billion deal to acquire Botox maker Allergan.

Apr 21, 2014 5:29PM on Top StocksBy MSN Money Partner

An activist investor and corporate acquirer may be teaming up to make an offer for Allergan.

Oct 3, 2013 8:24AM on Top StocksBy StreetAuthority

If you've ever wanted to invest alongside the best hedge funds, these simple investments allow you to do just that.

Sep 17, 2013 10:57AM on Top StocksBy MSN Money Partner

Kellogg is downgraded to 'underweight,' and Valeant is initiated with a 'conviction buy.'

Aug 8, 2013 10:16AM on Top StocksBy MSN Money Partner

Crocs is downgraded to 'underperform,' and Baxter is reinstated with a 'conviction buy.'

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More